Search Bar & Filters
Found 39 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying ASTX030, a combination of azacitidine and cedazuridine, alone or with venetoclax in people with myeloid neoplasms including myelodysplastic syndromes MDS, chronic myelomonocytic leukemia CMML, and acute myeloid leukemia AML. This multi-phase study includes phases 1 through 3 for monotherapy and phases 1 and 2 for combination therapy, aiming to evaluate the safety, pharmacokinetics, and effectiveness of these treatments over approximately 8 years. Participants receive various treatments depending on the study phase and arm. Treatments include oral doses of azacitidine, cedazuridine, ASTX030, subcutaneous azacitidine, and venetoclax in different sequences and cycles, typically lasting 28 days each. Some phases involve dose escalation and expansion stages, while others compare oral and subcutaneous forms or combine ASTX030 with venetoclax. Participants in certain arms may cross over to other treatments later in the study. During the study, participants undergo regular assessments including blood tests to measure drug levels, DNA methylation, and response rates such as complete remission. Researchers track adverse events, survival outcomes, transfusion independence, and pharmacokinetics up to 36 months or longer depending on the phase. Safety monitoring includes up to 24 months for some arms. The study involves scheduled visits for dosing and evaluations, with ongoing data collection to understand treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.
Actively Recruiting
Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.
Actively Recruiting
Researchers are investigating new treatment options for people with proficient mismatch repair pMMR endometrial cancer that is advanced or has returned after surgery. This cancer begins in the lining of the uterus and has either spread locally or to other parts of the body, making surgery not an option. The study aims to compare combining sacituzumab tirumotecan sac-TMT with pembrolizumab against pembrolizumab alone to see if it helps patients live longer without the cancer worsening. Participants first receive an Induction Phase treatment of six cycles every three weeks involving pembrolizumab plus either carboplatin or cisplatin combined with paclitaxel or docetaxel. If the cancer does not progress, they move to a Maintenance Treatment Phase where they are randomly assigned to receive pembrolizumab with sac-TMT or pembrolizumab alone. If the cancer progresses, participants may enter a Subsequent Treatment Phase with random assignment to pembrolizumab plus sac-TMT or sac-TMT alone. Treatments are given by intravenous infusion following specific dosing schedules over several months. Throughout the study, participants undergo regular assessments including scans to evaluate cancer progression, monitoring for side effects, and quality of life questionnaires. Researchers will measure progression-free survival and overall survival up to approximately 44 and 54 months respectively. The study also tracks adverse events and changes in physical and role functioning. The total participation can last up to several years with careful monitoring to assess treatment outcomes and safety.
Actively Recruiting
Researchers are conducting an international, multicenter, open-label phase III trial to evaluate the addition of adjuvant durvalumab after neoadjuvant chemotherapy combined with durvalumab and surgery in patients with early-stage, operable non-small cell lung cancer NSCLC stages IIB to IIIB. The main goal is to see if giving durvalumab after surgery improves disease-free survival in patients who do not achieve complete pathological response after initial treatment. The treatment plan involves 3 to 4 cycles of neoadjuvant durvalumab combined with platinum-based doublet chemotherapy, followed by surgery to remove the tumor. After surgery, patients with complete R0 or microscopic residual R1 resection are randomly assigned to either receive adjuvant durvalumab given intravenously at 1500 mg every 4 weeks for up to 12 cycles or to be observed without additional treatment. Participants will be monitored regularly for about 60 months after randomization to assess disease-free survival and other outcomes such as overall survival, time to recurrence, and treatment toxicity. Assessments include imaging scans to check for metastatic disease, pathological review after surgery, and ongoing safety evaluations. Participants must attend scheduled visits and follow study procedures throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the combination of setidegrasib with chemotherapy in adults who have metastatic pancreatic cancer with a specific KRAS G12D gene mutation. This mutation leads to abnormal proteins that may promote cancer growth. The study aims to find out if adding setidegrasib to standard chemotherapy improves survival compared to chemotherapy with a placebo. This trial is a phase 3, randomized, double-blind study focused on treatment outcomes in this patient population. Participants will receive either setidegrasib or a placebo once weekly along with one of two chemotherapy regimens, mFOLFIRINOX or NALIRIFOX, given in 28-day cycles through intravenous infusion. The choice of chemotherapy is determined by the study doctor. Treatment continues until cancer progression, intolerable side effects, start of other cancer therapies, participant or doctor decision to stop, or death. NALIRIFOX is given only after safety is confirmed with setidegrasib in another study. During the study, participants will have regular safety checks, medical assessments, and evaluations of their wellbeing. Researchers will measure overall survival up to 3.5 years, time to cancer progression, quality of life, pain improvement, response rates, adverse events, and pharmacokinetics of setidegrasib. The study includes extensive monitoring of laboratory values, vital signs, and heart function with electrocardiograms throughout the trial period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of standard chemotherapy combined with bevacizumab, with or without the addition of INCA33890, for the first-line treatment of adults with metastatic microsatellite stable colorectal cancer who have not received prior systemic treatment for metastatic disease. This phase 3 randomized, double-blind study aims to compare these treatment approaches to better understand their impact on disease progression. Participants will receive either INCA33890 or a placebo in combination with bevacizumab and FOLFOX chemotherapy at doses defined by the study protocol. The treatments are given as part of a randomized, parallel group design where neither the participants nor the investigators know which treatment is assigned. This study will assess outcomes over several years, with primary evaluation focused on progression-free survival for up to 3 years. Throughout the study, participants will be monitored regularly for treatment response, survival, and safety through various assessments including laboratory tests and quality of life questionnaires. Researchers will measure overall survival, objective response rate, duration of response, and treatment-related adverse events for up to 4 years. Quality of life changes will also be tracked using validated questionnaires. The total duration of participation may extend up to around 4 years, with ongoing safety and efficacy evaluations.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of pumitamig combined with chemotherapy compared to bevacizumab combined with chemotherapy in adults with previously untreated, unresectable, or metastatic colorectal cancer. This phase 23 study aims to provide important information on treatment options for this type of advanced colorectal cancer. Participants will receive different combinations of study drugs, including pumitamig or bevacizumab, along with chemotherapy regimens such as FOLFOX, FOLFIRI, or CAPOX. The dosages are specified and given on designated days. The study uses a randomized, double-blind design to compare these treatments across multiple groups. During the study, participants will be closely monitored for tumor response, progression-free survival, and overall survival for up to five years. Evaluations include tumor measurements using RECIST criteria, safety assessments, and other clinical tests. This long-term follow-up helps researchers understand how well the treatments work and their effects over time.
Actively Recruiting
Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.
Actively Recruiting
Researchers are evaluating two types of stereotactic body radiotherapy SBRT in men with high risk localized prostate cancer, where the cancer is confined to the prostate but may grow quickly or spread. The study aims to compare the safety and effectiveness of delivering radiotherapy to the prostate alone versus the prostate plus surrounding lymph nodes, with both treatments given in only 5 sessions. This phase III trial is designed to see if including lymph nodes reduces the chance of cancer returning and to review any side effects that occur. Participants will be randomly assigned to one of two groups. One group will receive SBRT targeting the prostate and seminal vesicles, delivering 36.25Gy in 5 fractions on alternate days with 40Gy to the prostate clinical target volume. The other group will get the same prostate treatment plus 25Gy in 5 fractions to the pelvic lymph nodes on alternate days. Treatments will be provided over approximately two weeks at experienced NHS radiotherapy centers that meet quality standards for these therapies. During the study, participants will be monitored for at least three and a half years to assess time to biochemical or clinical failure, which is the main outcome. Researchers will also track acute and late side effects, cancer relapse, survival rates, patient-reported outcomes, and adherence to treatment protocols for up to five years post-randomization. Regular imaging and assessments will be performed before treatment to confirm eligibility and exclude metastatic disease. Overall, participants can expect close monitoring and follow-up throughout and after their treatment period.
1-10 of 39
1